Business
Eli Lilly stock disappoints as obesity drug sales disappoint.
Eli Lilly
Shares fell on Thursday as the drug company’s heavily hyped obesity drug sales fell short. However, fourth-quarter earnings exceeded estimates.
Eli Lilly
(ticker: LLY) fell 2.9% in premarket trading. Futures contract tracking
S&P 500
rose 0.5%, by comparison.